Top

Published in:

Open Access 01-07-2019 | Heart Failure

Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost–utility analyses

Authors: Jenny Rankin, Donna Rowen, Amanda Howe, John G. F. Cleland, Jennifer A. Whitty

Published in: Heart Failure Reviews | Issue 4/2019

Abstract

The accurate measurement of health-related quality of life (HRQoL) and the value of improving it for patients are essential for deriving quality-adjusted life years (QALYs) to inform treatment choice and resource allocation. The objective of this review was to identify and describe the approaches used to measure and value change in HRQoL in trial-based economic evaluations of heart failure interventions which derive QALYs as an outcome. Three databases (PubMed, CINAHL, Cochrane) were systematically searched. Twenty studies reporting economic evaluations based on 18 individual trials were identified. Most studies (n = 17) utilised generic preference-based measures to describe HRQoL and derive QALYs, commonly the EQ-5D-3L. Of these, three studies (from the same trial) also used mapping from a condition-specific to a generic measure. The remaining three studies used patients’ direct valuation of their own health or physician-reported outcomes to derive QALYs. Only 7 of the 20 studies reported significant incremental QALY gains. Most interventions were reported as being likely to be cost-effective at specified willingness to pay thresholds. The substantial variation in the approach applied to derive QALYs in the measurement of and value attributed to HRQoL in heart failure requires further investigation.

Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G (2014) Heart failure: preventing disease and death worldwide. ESC Heart Fail 1(1):4–25. https://doi.org/10.1002/ehf2.12005

NICE (2013) Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence (NICE), London

Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ (2010) A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes 8:13. https://doi.org/10.1186/1477-7525-8-13 CrossRefPubMedPubMedCentral

Eurich DT, Johnson JA, Reid KJ, Spertus JA (2006) Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes 4:89. https://doi.org/10.1186/1477-7525-4-89 CrossRefPubMedPubMedCentral

Payakachat N, Ali MM, Tilford JM (2015) Can the EQ-5D detect meaningful change? A systematic review. Pharmacoeconomics 33:1137–1154. https://doi.org/10.1007/s40273-015-0295-6 CrossRefPubMedPubMedCentral

Green CP, Porter CB, Bresnahan DR, Spertus JA (2000) Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 35:1245–1255CrossRefPubMed

Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, McCullough P, Pina I, Tooley J, Weintraub WS, Rumsfeld JS, Cardiovascular Outcomes Research Consortium (2005) Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J 150:707–715. https://doi.org/10.1016/j.ahj.2004.12.010 CrossRefPubMed

Berry C, McMurray J (1999) A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics 16:247–271CrossRefPubMed

Rowen D, Brazier J, Ara R, Azzabi Zouraq I (2017) The role of condition-specific preference-based measures in health technology assessment. Pharmacoeconomics 35:33–41. https://doi.org/10.1007/s40273-017-0546-9 CrossRefPubMed

10.

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E, ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 16:231–250. https://doi.org/10.1016/j.jval.2013.02.002 CrossRef

11.

Blomström P, Ekman M, Lundqvist CB, Calvert MJ, Freemantle N, Lönnerholm S, Wikström G, Jönsson B (2008) Cost effectiveness of cardiac resynchronization therapy in the Nordic region: an analysis based on the CARE-HF trial. Eur J Heart Fail 10:869–877CrossRefPubMed

12.

Calvert M, Freemantle N, Yao G, Cleland JG, Billingham L, Daubert JC, Bryan S, CARE-HF investigators (2005) Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 26:2681–2688CrossRefPubMed

13.

Maniadakis N, Ekman M, Calvert MJ, Freemantle N, Karamalis M, Vardas P (2011) Cost effectiveness of cardiac resynchronization therapy in Greece: an analysis based on the CArdiac REsychronization in Heart Failure trial. Europace 13:1597–1603. https://doi.org/10.1093/europace/eur188 CrossRefPubMed

14.

Cleland J, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L, Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539–1549CrossRefPubMed

15.

Capomolla S, Febo O, Ceresa M, Caporotondi A, Guazzotti G, la Rovere MT, Ferrari M, Lenta F, Baldin S, Vaccarini C, Gnemmi M, Pinna GD, Maestri R, Abelli P, Verdirosi S, Cobelli F (2002) Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care. J Am Coll Cardiol 40:1259–1266CrossRefPubMed

16.

Hansson E, Ekman I, Swedberg K, Wolf A, Dudas K, Ehlers L, Olsson LE (2016) Person-centred care for patients with chronic heart failure—a cost-utility analysis. Eur J Cardiovasc Nurs 15:276–284CrossRefPubMed

17.

Postmus D, Abdul Pari AA, Jaarsma T, Luttik ML, van Veldhuisen DJ, Hillege HL, Buskens E (2011) A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. Am Heart J 162:1096–1104CrossRefPubMed

18.

Sahlen KG, Boman K, Brannstrom M (2016) A cost-effectiveness study of person-centered integrated heart failure and palliative home care: based on a randomized controlled trial. Palliat Med 30:296–302. https://doi.org/10.1177/0269216315618544 CrossRefPubMed

19.

Agvall B, Paulsson T, Foldevi M, Dahlstrom U, Alehagen U (2014) Resource use and cost implications of implementing a heart failure program for patients with systolic heart failure in Swedish primary health care. Int J Cardiol 176:731–738. https://doi.org/10.1016/j.ijcard.2014.07.105 CrossRefPubMed

20.

Boyne JJ, di van Asselt A, Gorgels APM, Steuten LMG, de Weerd G, Kragten J, Vrijhoef HJM (2013) Cost-effectiveness analysis of telemonitoring versus usual care in patients with heart failure: the TEHAF-study. J Telemed Telecare 19:242–248. https://doi.org/10.1177/1357633X13495478 CrossRefPubMed

21.

Hebert PL, Sisk JE, Wang JJ, Tuzzio L, Casabianca JM, Chassin MR, Horowitz C, McLaughlin M (2008) Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community. Ann Intern Med 149:540–548CrossRefPubMedPubMedCentral

22.

Maru S, Byrnes J, Carrington MJ, Chan YK, Thompson DR, Stewart S, Scuffham PA, WHICH? Trial Investigators (2015) Cost-effectiveness of home versus clinic-based management of chronic heart failure: extended follow-up of a pragmatic, multicentre randomized trial cohort—the WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care). Int J Cardiol 201:368–375. https://doi.org/10.1016/j.ijcard.2015.08.066 CrossRefPubMed

23.

Mejia A, Richardson G, Pattenden J, Cockayne S, Lewin R (2014) Cost-effectiveness of a nurse facilitated, cognitive behavioural self-management programme compared with usual care using a CBT manual alone for patients with heart failure: secondary analysis of data from the SEMAPHFOR trial. Int J Nurs Stud 51:1214–1220. https://doi.org/10.1016/j.ijnurstu.2014.01.009 CrossRefPubMed

24.

Neumann A, Mostardt S, Biermann J, Gelbrich G, Goehler A, Geisler BP, Siebert U, Störk S, Ertl G, Angerrmann CE, Wasem J (2015) Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. Clin Res Cardiol 104:304–309. https://doi.org/10.1007/s00392-014-0781-4 CrossRefPubMed

25.

Patel H, Shafazand M, Ekman I, Höjgård S, Swedberg K, Schaufelberger M (2008) Home care as an option in worsening chronic heart failure—a pilot study to evaluate feasibility, quality adjusted life years and cost-effectiveness. Eur J Heart Fail 10:675–681. https://doi.org/10.1016/j.ejheart.2008.05.012 CrossRefPubMed

26.

Reilly CM, Butler J, Culler SD, Gary RA, Higgins M, Schindler P, Butts B, Dunbar SB (2015) An economic evaluation of a self-care intervention in persons with heart failure and diabetes. J Card Fail 21:730–737. https://doi.org/10.1016/j.cardfail.2015.06.382 CrossRefPubMedPubMedCentral

27.

Cui Y, Doupe M, Katz A, Nyhof P, Forget EL (2013) Economic evaluation of Manitoba health lines in the management of congestive heart failure. Healthcare Policy 9(2):36–50

28.

Zanaboni P, Landolina M, Marzegalli M, Lunati M, Perego G et al (2013) Cost-utility analysis of the EVOLVO study on remote monitoring for heart failure patients with implantable defibrillators: randomized controlled trial. J Med Internet Res 15(5):e106:1–11

29.

Reed S et al (2010) Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes 3:374–381CrossRefPubMedPubMedCentral

30.

Sanders-van Wijk S, van Asselt A, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Vuillomenet A, Peter M, Pfisterer ME, Brunner-la Rocca HP, TIME-CHF Investigators (2013) Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). JACC Heart Fail 1:64–71. https://doi.org/10.1016/j.jchf.2012.08.002 CrossRefPubMed

31.

Sánchez J et al (2010) Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant 25:605–610CrossRefPubMed

32.

Alehagen U, Rahmqvist M, Paulsson T, Levin LA (2008) Quality-adjusted life year weights among elderly patients with heart failure. Eur J Heart Fail 10:1033–1039. https://doi.org/10.1016/j.ejheart.2008.07.015 CrossRefPubMed

33.

Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108CrossRefPubMed

34.

Brazier J, Roberts J, Deverill M (2002) The estimation of a preference-based measure of health from the SF-36. J Health Econ 21:271–292CrossRefPubMed

35.

Franks P, Lubetkin E, Gold M, Tancredi D (2003) Mapping the SF-12 to preference-based instruments: convergent validity in a low-income, minority population. Med Care 41:1277–1283CrossRefPubMed

36.

Viney R, Norman R, King MT, Cronin P, Street DJ, Knox S, Ratcliffe J (2011) Time trade-off derived EQ-5D weights for Australia. Value Health 14:928–936. https://doi.org/10.1016/j.jval.2011.04.009 CrossRefPubMed

37.

Shaw JW, Johnson JA, Coons SJ (2005) US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43:203–220CrossRefPubMed

38.

Kind P (2003) Guidelines for value sets in economic non-economic studies using EQ-5D. In: Brooks R, Rabin R, de Charro F (eds) The measurement and valuation of health status using EQ-5D: a European perspective. Kluwer Academic Publishers, Dordrecht

39.

Sandhu AT, Goldhaber-Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA (2016) Cost-effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. JACC Heart Fail 4:368–375. https://doi.org/10.1016/j.jchf.2015.12.015 CrossRefPubMedPubMedCentral

40.

Scuffham PA, Whitty JA, Mitchell A, Viney R (2008) The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002–4. Pharmacoeconomics 26:297–310CrossRefPubMed

41.

Rowen D, Azzabi Zouraq I, Chevrou-Severac H, van Hout B (2017) International regulations and recommendations for utility data for health technology assessment. Pharmacoeconomics 35:11–19. https://doi.org/10.1007/s40273-017-0544-y CrossRefPubMed

42.

Rector TS, Kubo S et al (1987) Patients’ self-assessment of their congestive heart failure. Part 2: content, reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Fail 3:198–209

43.

Kularatna S, Byrnes J, Chan YK, Carrington MJ, Stewart S, Scuffham PA (2017) Comparison of contemporaneous responses for EQ-5D-3L and Minnesota Living with Heart Failure; a case for disease specific multiattribute utility instrument in cardiovascular conditions. Int J Cardiol 227:172–176. https://doi.org/10.1016/j.ijcard.2016.11.030 CrossRefPubMed

44.

Mejhert M, Kahan T, Persson H, Edner M (2004) Limited long term effects of a management programme for heart failure. Heart. 90:1010–1015CrossRefPubMedPubMedCentral

45.

Dolan P, Sutton M (1997) Mapping visual analogue scale health state valuations onto standard gamble and time trade-off values. Soc Sci Med 44:1519–1530CrossRefPubMed

46.

Longworth L, Rowen D (2013) Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health 16:202–210. https://doi.org/10.1016/j.jval.2012.10.010 CrossRef

47.

Feldman AM, de Lissovoy G, Bristow MR, Saxon LA, de Marco T, Kass DA, Boehmer J, Singh S, Whellan DJ, Carson P, Boscoe A, Baker TM, Gunderman MR (2005) Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 46:2311–2321. https://doi.org/10.1016/j.jacc.2005.08.033 CrossRefPubMed

48.

Moertl D, Steiner S, Coyle D, Berger R (2013) Cost-utility analysis of nt-probnp-guided multidisciplinary care in chronic heart failure. Int J Technol Assess Health Care 29:3–11CrossRefPubMed

49.

Brazier J, Yang Y, Tsuchiya A, Rowen DL (2010) A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ 11:215–225. https://doi.org/10.1007/s10198-009-0168-z CrossRef

50.

Clarke A, Pulikottil-Jacob R, Connock M, Suri G, Kandala NB, Maheswaran H, Banner NR, Sutcliffe P (2014) Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program. Int J Cardiol 171:338–345. https://doi.org/10.1016/j.ijcard.2013.12.015 CrossRefPubMed

51.

Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG (2007) The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 28:42–51CrossRefPubMed

52.

Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, Botteman M, Busschbach J (2017) Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health 20:18–27. https://doi.org/10.1016/j.jval.2016.11.006 CrossRef

53.

Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A (2015) Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statement. J Med Econ 18:851–857. https://doi.org/10.3111/13696998.2015.1070554 CrossRefPubMed

54.

Ara R, Rowen D, Mukuria C (2017) The use of mapping to estimate health state utility values. Pharmacoeconomics 35:57–66. https://doi.org/10.1007/s40273-017-0548-7 CrossRef

55.

Sculpher M, Gafni A (2001) Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ 10:317–324CrossRefPubMed

56.

Sculpher M, Gafni A (2002) Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Author’s reply. Health Econ 11:653–654CrossRef

57.

Robinson A, Parkin D (2002) Recognising diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. A response to Sculpher and Gafni. Health Econ 11:649–651CrossRefPubMed

58.

Cleland JG, Charlesworth A, Lubsen J, Swedberg K, Remme WJ, Erhardt L, di Lenarda A, Komajda M, Metra M, Torp-Pedersen C, Poole-Wilson PA, COMET Investigators (2006) A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the “patient journey”) in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). J Am Coll Cardiol 47:1603–1611. https://doi.org/10.1016/j.jacc.2005.11.069 CrossRefPubMed

Title: Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost–utility analyses
Authors: Jenny Rankin
Donna Rowen
Amanda Howe
John G. F. Cleland
Jennifer A. Whitty
Publication date: 01-07-2019
Publisher: Springer US
Keyword: Heart Failure
Published in: Heart Failure Reviews / Issue 4/2019
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-019-09780-7

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost–utility analyses

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Nutrition intervention in heart failure: should consumption of the DASH eating pattern be recommended to improve outcomes?

Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement

Effects of European Society of Cardiology guidelines on medication profiles after hospitalization for heart failure in 22,476 Dutch patients: from 2001 until 2015

Experimental models of cardiac physiology and pathology

Personalized physiology-guided resuscitation in highly monitored patients with cardiac arrest—the PERSEUS resuscitation protocol

Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page